Journal of Clinical Oncology
Federico Mercolini, Marissa Just, Barry L. Shulkin, Natalie B. Collins, Jacquelyn Crane, Douglas Harrison, Maria C. Affinita, Wendy Allen-Rhoades, Alessandra Alessi, Sebastian D. Asaftei, Michael A. Arnold, Sonja Chen, Stefano Chiaravalli, Forrest FitzGerald, Martin T. Freitag, Jessica L. Iftner, Hedieh Khalatbari, Bart de Keizer, Irene von Luettichau, Christine Mauz-Körholz, Claudia Rossig, Guido Rovera, Stefan Rutkowski, Justin B. Sims, Stephan D. Voss, Ayami Yoshimi, Suzi Birz, Gianni Bisogno, Martin Ebinger, Johannes H.M. Merks, Monika Sparber-Sauer, Bernhard Haller, Aaron R. Weiss, Corinne M. Linardic, Reineke A. Schoot, Simone Hettmer, for the INSTRuCT Imaging/Pathology/Biology Network, Giorgio Baldari, Isabel Borrego-Dorado, Nicodemo Baffa
PURPOSE Detection of bone marrow disease has been a major component of rhabdomyosarcoma (RMS) staging with bilateral bone marrow aspirates/biopsies (BMAB) from the iliac crests considered the diagnostic gold standard. This study's goal was to determine if 2- 18 F-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) or PET/magnetic resonance imaging (MRI) may replace BMAB in RMS staging. METHODS Patients were recruited in Europe and North America. Medical records, FDG PET/C …